Fluorescence Imaging News and Research

RSS

LifeCell, Novadaq Technologies sign exclusive sales, marketing agreement

LifeCell Corporation, a business unit of Kinetic Concepts, Inc., and Novadaq Technologies Inc. announced today the signing of an exclusive sales and marketing agreement for distribution of Novadaq's SPY Imaging System in North American surgical markets. LifeCell will drive adoption for the SPY System in breast reconstructive, head and neck, and colorectal surgical specialties, with more than half a million procedures projected annually.

2 Sep 2010

New study of breast cancer survivors may help physicians ease side effect of treatments

A new study of breast cancer survivors may help physicians ease a common side effect of cancer treatments. The collaborative research by Eva Sevick, Ph.D., Director of the Center for Molecular Imaging at the University of Texas Health Science Center in Houston, and Caroline Fife, M.D., Director of the Memorial Herman Wound Care Clinic at UTHSC, could bring relief to millions.

4 Aug 2010

Thermo Fisher Scientific introduces low evaporation plates for cell culture and high content analysis

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the Thermo Scientific Nunc Edge 96-well Plates for cell-based assays.

From Thermo Fisher Scientific Inc. 29 Jul 2010

VisEn Medical announces launch of two new imaging agents at EMIM 2010

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced the commercial launch of two new imaging agents -- ProSense® 750 FAST for expanded versatility in imaging cathepsin activity, and Neutrophil Elastase™ 680 FAST, for imaging of inflammatory elastase activity associated with disease progression and therapeutic response. The launch announcements were made at the European Molecular Imaging Meeting (EMIM) 2010 in Warsaw, Poland.

26 May 2010

Fluorescent inhibitors hold promise for early-stage tumor detection

A series of novel imaging agents could light up tumors as they begin to form - before they turn deadly - and signal their transition to aggressive cancers.

29 Apr 2010

VisEn Medical expands FMT imaging platform

VisEn Medical Inc., a leader in fluorescence imaging solutions from research through medicine, announced today that it has expanded its leading FMT imaging platform with an FMT™ Multi-Species Imaging Module, to extend FMT imaging and related applications into larger preclinical animal models. VisEn also announced that it will be presenting new study results from its recently-launched Cat B 750 FAST™ and Annexin-Vivo™ fluorescence imaging agents at the AACR 101st Annual Meeting.

16 Apr 2010

New medical imaging technique using pulsed laser and nanocages

New research findings suggest that an experimental ultrasensitive medical imaging technique that uses a pulsed laser and tiny metallic "nanocages" might enable both the early detection and treatment of disease.

13 Apr 2010

VisEn Medical announces launch of new GastroSense 750 fluorescence agent for imaging gastric motility

VisEn Medical Inc., a leader in fluorescence imaging from research through medicine, announced today the commercial launch of its new GastroSense™ 750 fluorescence agent for imaging gastric motility and related drug effects in vivo.

26 Mar 2010

VisEn Medical introduces VivoTag 680 XL fluorescent dye for labeling biomolecules

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new VivoTag® 680 XL fluorescent dye for labeling biomolecules in a broad range of in vitro and in vivo imaging applications.

12 Mar 2010

Calcium waves could be relevant for understanding the origin of Alzheimer's disease

New insights on what causes Alzheimer's disease could arise from a recent discovery made by bioengineers from the University of California, San Diego. The finding concerns the infamous amyloid beta peptides (Aβ)-fragments of which form plaques thought to play a role in Alzheimer's disease.

15 Feb 2010

VisEn Medical acquires Bayer Schering Pharma AG's fluorescence agent intellectual property portfolios

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today that it has acquired the fluorescence imaging agent intellectual property portfolios and related technology platforms from Bayer Schering Pharma AG, Germany.

29 Jan 2010

VisEn Medical announces the commercial launch of new Cat B 680 FAST imaging agent

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new Cat B 680 FAST™ imaging agent for measuring and monitoring cathepsin B activity associated with disease progression and therapeutic response in vivo.

21 Jan 2010

Image of a water flea wins top prize in the 2009 Olympus BioScapes Digital Imaging Competition

A glowing, eerily beautiful image of a water flea with its radiant green "crown of thorns" took top prize in the 2009 Olympus BioScapes Digital Imaging Competition®, the world's foremost forum for showcasing microscope photos and movies of life science subjects. Dr. Jan Michels, a zoologist at the University of Albrecht, Kiel, Germany, took top honors for the image of a water flea, with its defensive "crown of thorns" to protect it against predators. The image reveals not only the exoskeleton, but also interior detail down to the nuclei within its cells, seen as tiny, glowing blue dots. This

From Evident Corporation - Life Sciences 20 Nov 2009

VisEn Medical launches two new agents for imaging quantification

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new OsteoSense® 800 imaging agent for targeting areas of bone turnover and microcalcification in vivo. The new 800 nm OsteoSense agent complements VisEn's OsteoSense 680 and 750 products, and is expected to further expand the utilization of this agent family in enabling in vivo detection, measurement and monitoring of skeletal changes in a wide range of disease states, including arthritis, osteoporosis, and cancer metastasis.

19 Nov 2009

New Cat B 750 FAST imaging agent launched by VisEn Medical

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new Cat B 750 FAST(TM) imaging agent for measuring and monitoring cathepsin B activity associated with disease progression and therapeutic response in vivo. Cathepsin B expression is well known as a key biomarker and therapeutic target in a range of diseases, including atherosclerosis, oncology, and arthritis.

12 Nov 2009

Innovative optical system to study the complex mechanisms that lead to sudden cardiac arrest developed

A research team at Vanderbilt University has developed an innovative optical system to simultaneously image electrical activity and metabolic properties in the same region of a heart, to study the complex mechanisms that lead to sudden cardiac arrest.

31 Oct 2009

Hamamatsu to release its NanoZoomer 2.0 series slide scanners

Hamamatsu Corporation has announced the release of its next-generation slide scanners, the NanoZoomer 2.0 series. Operating at nearly twice the speed of the original series, the NanoZoomer 2.0 converts a 20 mm x 20 mm area on a glass slide into a 1.9-gigapixel color image in as little as 1 minute 40 seconds.

8 Oct 2009

VisEn launches new imaging agent for monitoring key hypertension and renal disease biomarker

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new ReninSense680(TM) FAST imaging agent for measuring and monitoring a key hypertension and renal disease biomarker in vivo.

24 Sep 2009

Magnetic nanoworms and nanocrystals deliver siRNA to tumors

Small pieces of nucleic acid known as short interfering RNAs, or siRNAs, can turn off the production of specific proteins, a property that makes them one of the more promising new classes of anticancer drugs in development. Indeed, at least two siRNA-based anticancer therapies, both delivered to tumors in nanoparticles, have begun human clinical trials.

23 Sep 2009

New Fluorescence Molecular Tomography imaging systems from VisEn Medical

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced the launch and availability of a new Fluorescence Molecular Tomography (FMT) imaging system -- the FMT 1500, and an advanced version of its FMT 2500, the FMT 2500 LX.